https://scholars.lib.ntu.edu.tw/handle/123456789/592392
標題: | Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer | 作者: | TZU-TANG WEI Lin, Yi-Ting Chen, Wen-Shu Luo, Ping Lin, Yu-Chin CHIA-TUNG SHUN Lin, Yi-Hsin Chen, Jhih-Bin Chen, Nai-Wei Fang, Jim-Min MING-SHIANG WU KAI-CHIEN YANG LI-CHUN CHANG Tai, Kang-Yu JIN-TUNG LIANG CHING-CHOW CHEN |
關鍵字: | Colorectal cancer; HMG-CoA reductase; Histone deacetylase; Preclinical model; Statin hydroxamate | 公開日期: | 八月-2016 | 出版社: | ELSEVIER SCIENCE BV | 卷: | 10 | 起(迄)頁: | 124 | 來源出版物: | EBioMedicine | 摘要: | Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR) inhibitors decreasing serum cholesterol and have shown promise in cancer prevention. In this study, we demonstrated the oncogenic role of HMGR in colorectal cancer (CRC) by disclosing increased HMGR activity in CRC patients and its enhancement of anti-apoptosis and stemness. Our previous studies showed that statins containing carboxylic acid chains possessed activity against histone deacetylases (HDACs), and strengthened their anti-HDAC activity through designing HMGR-HDAC dual inhibitors, JMF compounds. These compounds exerted anti-cancer effect in CRC cells as well as in AOM-DSS and Apc(Min/+) CRC mouse models. JMF mostly regulated the genes related to apoptosis and inflammation through genome-wide ChIP-on-chip analysis, and Ingenuity Pathways Analysis (IPA) predicted their respective regulation by NR3C1 and NF-κB. Furthermore, JMF inhibited metastasis, angiogenesis and cancer stemness, and potentiated the effect of oxaliplatin in CRC mouse models. Dual HMGR-HDAC inhibitor could be a potential treatment for CRC. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/592392 | ISSN: | 23523964 | DOI: | 10.1016/j.ebiom.2016.07.019 | SDG/關鍵字: | histone deacetylase; histone deacetylase inhibitor; hydroxamic acid; hydroxymethylglutaryl coenzyme A reductase; jmf3086; jmf3171; jmf3173; mevinolin; oxaliplatin; unclassified drug; antineoplastic agent; histone deacetylase; histone deacetylase inhibitor; hydroxymethylglutaryl coenzyme A reductase; hydroxymethylglutaryl coenzyme A reductase inhibitor; angiogenesis; animal cell; animal experiment; animal model; apoptosis; Article; chromatin immunoprecipitation; colorectal cancer; down regulation; drug targeting; female; HCT 116 cell line; inflammation; liver metastasis; male; mouse; nonhuman; priority journal; protein microarray; tumor microenvironment; tumor xenograft; animal; cancer stem cell; Colorectal Neoplasms; disease model; drug effects; drug screening; gene expression regulation; genetics; genome-wide association study; human; metabolism; metastasis; molecularly targeted therapy; pathology; preclinical study; transgenic mouse; Animals; Antineoplastic Agents; Colorectal Neoplasms; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Transgenic; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplastic Stem Cells; Xenograft Model Antitumor Assays |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。